LATEST

• REGULATORY MHLW Seeks Sponsors to Develop 8 “Drug-Loss” Products
  March 2, 2026

• BUSINESS Shionogi, Torii File Lotion Form of Corectim in Japan
  March 2, 2026

• REGULATORY WG Members Urge Domestic Biologic Production as National Growth Strategy
  March 2, 2026

• REGULATORY MHLW Clarifies Up to 12-Year Data Protection for Pediatric Development
  March 2, 2026

• REGULATORY MHLW Issues 15 Notices Ahead of PMD Act Amendment
  March 2, 2026

• BUSINESS Arcalis Completes mRNA Drug Facility, Establishes End-to-End CDMO Platform
  March 2, 2026

• REGULATORY Celltrion’s Eylea Biosimilar Nears Approval, but Listing Outlook Clouded
  February 27, 2026

• REGULATORY Japan Panel to Review Joenja, Dojolvi for Approval at March 5 Session
  February 27, 2026

• BUSINESS GSK Files Hep B Drug in Japan as First Global Submission
  February 27, 2026

• REGULATORY Executives Urge Stronger CDMO, CRO Base at Drug Discovery WG Meeting
  February 27, 2026

• BUSINESS Astellas Doubles Labor Productivity Since FY2020, Credits Organization Rejig
  February 27, 2026

• BUSINESS Sumitomo Regains DSP-0187 Rights as Jazz Calls Off Deal
  February 27, 2026

• REGULATORY Japan to Closely Monitor US “MFN” Policy: PM Takaichi
  February 27, 2026

• REGULATORY Japan to Update Adult Pneumococcal Fact Sheet Ahead of Capvaxive NIP Review
  February 27, 2026

• BUSINESS Asahi Kasei to Buy German Antiviral Specialist Aicuris for 143.1 Billion Yen
  February 27, 2026

• BUSINESS Daiichi Sankyo Chair Manabe to Step Down in June
  February 27, 2026

• BUSINESS Japan Pharma Market Up 1.7% in 2025, 5th Straight Year of Growth: IQVIA
  February 26, 2026

• REGULATORY Takaichi Signals Continued Off-Year Revisions despite Abolition Calls
  February 26, 2026

• BUSINESS Sawai to End Teribone Generic Sales following Patent Settlement
  February 26, 2026

• BUSINESS Darzquro Seen as Emerging Standard in High-Risk SMM: Specialist
  February 26, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• Next ›
• 最終 »